期刊文献+

原发性血小板增多症患者血小板单采术前后血液学指标观察

原文传递
导出
摘要 目的观察原发性血小板增多症患者经血小板单采术治疗对血常规、生化及凝血功能等血液指标的影响。方法对因原发性血小板增多症进行血小板单采术治疗的28例患者,检测血小板单采前及单采后2h血常规、生化及止凝血功能等血液指标并分析比较。结果28例患者血小板单采后2h:(1)血小板计数(PLT)明显下降(P〈0.01),白细胞(WBC)、红细胞(RBC)、血红蛋白(Hb)无明显变化(P〉0.05)。(2)血钾、血镁下降(P〈0.05),血钙明显下降(P〈0.01),血钠、氯、血糖无明显变化(P〉0.05)。(3)AgTT、PT明显延长(P〈0.001),FIB含量增高(P〈0.05)。结论血小板单采术治疗原发性血小板增多症可明显降低血小板数量,疗效显著;但单采治疗后可出现血钾、镁、钙降低,APTT、PT时间延长,要密切监测生化及止凝血功能等血液指标变化,防止电解质紊乱、出血等不良后果出现。
作者 李乔 曾欣
出处 《中国医师杂志》 CAS 2013年第1期118-119,共2页 Journal of Chinese Physician
  • 相关文献

参考文献9

  • 1叶任高;陆再英.内科学[M]北京:人民卫生出版社,2000640-641.
  • 2祝平安,梁欣泉.原发性血小板增多症13例疗效分析[J].医学临床研究,2004,21(2):160-161. 被引量:2
  • 3Reilly JT. Current treatment practices for essential thrombocythemia:survey results from European hematologists/oncologists[J].Hematology,2012,(04):187-192.
  • 4Winters JL. Complications of donor apheresis[J].Journal of Clinical Apheresis,2006,(02):132-141.doi:10.1002/jca.20039.
  • 5Das SS,Chaudhary R,Khetan D. Calcium and magnesium levels during autom atedplateletpheres is in normal donors[J].Transfusion Medicine,2005,(03):233-236.doi:10.1111/j.1365-3148.2005.00576.x.
  • 6张之南;沈悌.血液病诊断及疗效标准[M]北京:科学出版社,1998940.
  • 7黄莉,姚红霞,林丽娥.原发性血小板增多症31例临床分析[J].血栓与止血学,2010,16(2):72-74. 被引量:3
  • 8夏云金,周梅玲,万楚成,章正华,张霞,姜铧,龙志国.治疗性血小板单采术在血小板增多症患者中的应用[J].血栓与止血学,2011,17(6):266-268. 被引量:10
  • 9Bolan CD,Cecco SA,Yau YY. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis Ⅱ Metabolic effects[J].Transfusion,2003,(10):1414-1422.doi:10.1046/j.1537-2995.2003.00513.x.

二级参考文献12

  • 1陈晓虹,郭丰,李忠.血栓素A_2合成酶抑制剂治疗合并原发性血小板增多症的脑梗死1例报道[J].卒中与神经疾病,2005,12(4):219-219. 被引量:5
  • 2ARELLANO- RODRIGO E, ALVAREZ- LARRAN A, REVERTER JC, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden [ J ]. Am J Hematol, 2009,84 ( 2 ) : 102-108.
  • 3PALANDRI F,OTTAVIANI E,SALMI F, et al. JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients [ J ]. Leuk Lymphoma, 2009,50 ( 2 ) : 247- 253.
  • 4VARDIMAN JW, HARRIS NL, BRUNNING RD. The World Health Organization ( WHO ) classification of the myeloid neoplasms [ J ]. Blood, 2002,100 ( 7 ) :2292- 2302.
  • 5张之南,沈悌.血液病诊断及疗效标准[M].第三版.北京:科学出版社,2008:181-183.
  • 6JOHANSSON P. Epidemiology of the myeloproliferative disorders polyeytothemia vera and essential thromboeythemia [ J ]. Sem Thromb Haemost, 2006, 32 ( 3 ) : 171 - 173.
  • 7BARBUI T, BAROSI G, GROSSI A, et al. Practice guidelines for the therapy of essential thrombocythemia : a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation [ J ]. Haematologica, 2004,89 : 215- 232.
  • 8BAXTER E J, SCOTT LM, CAMPBELL PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders[ J ]. Lancet, 2005,365 : 1054-1061.
  • 9Murphy S, Peterson P, Iland H,et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria,survival, and leukemia transition by treatment[J].Semin Hematol,1997,34(1):29-39.
  • 10杨仁池,华宝来,钱林生,李大鹏.原发性血小板增多症94例临床分析[J].临床血液学杂志,2000,13(1):8-10. 被引量:29

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部